Companies researching Ocrevus (ocrelizumab)

Ocrevus (ocrelizumab) is a humanized anti‑CD20 monoclonal antibody employed as an immunosuppressive therapy for multiple sclerosis.

List of companies that research Ocrevus (ocrelizumab)

This is sourced from job postings — companies only hire for what they actively use or plan to adopt · how we source this →

CompanyCountryIndustryEmployeesRevenueTechnologies
Country flag

Australia

Hospitals and Health Care

730

Ocrevus (ocrelizumab)

Country flag

United States

Higher Education

13k

$2.3B

Ocrevus (ocrelizumab)

Country flag

United States

Hospitals and Health Care

51

$2M

Ocrevus (ocrelizumab)

Country flag

Switzerland

Biotechnology Research

105k

$68B

Ocrevus (ocrelizumab)

Country flag

United States

Hospitals and Health Care

201

Ocrevus (ocrelizumab)

Country flag

United Kingdom

Hospitals and Health Care

193k

$105B

Ocrevus (ocrelizumab)

Country flag

United States

Hospitals and Health Care

6.3k

$300M

Ocrevus (ocrelizumab)

Country flag

United States

Biotechnology Research

21k

$26B

Ocrevus (ocrelizumab)

Country flag

United States

Professional Services

2.7k

$400M

Ocrevus (ocrelizumab)

Country flag

United States

IT Services and IT Consulting

201

$27M

Ocrevus (ocrelizumab)

Showing top companies out of 32 that research Ocrevus (ocrelizumab). Get the full list on TheirStack.

Frequently asked questions